{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:02:33Z","timestamp":1790827353765,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473010"],"award-info":[{"award-number":["82473010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573655"],"award-info":[{"award-number":["82573655"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["2024DFYCKJPT_XDM"],"award-info":[{"award-number":["2024DFYCKJPT_XDM"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011930","name":"Beijing Medical and Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["25ZR1401306"],"award-info":[{"award-number":["25ZR1401306"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.critrevonc.2026.105152","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T15:33:20Z","timestamp":1769355200000},"page":"105152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Multifaceted mechanisms and precision strategies to overcome therapeutic resistance in gallbladder cancer"],"prefix":"10.1016","volume":"219","author":[{"given":"Qingliang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-8082","authenticated-orcid":false,"given":"Daimin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","article-title":"Advances in liquid biopsy: from exploration to practical application","volume":"43","author":"Alix-Panabi\u00e8res","year":"2025","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105152_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: a promising actionable target in biliary tract cancers","volume":"10","author":"Angerilli","year":"2025","journal-title":"ESMO Open"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105152_bib4","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRAS(G12C) Inhibition in Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10616-017-0160-x","article-title":"Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K\/AKT\/ERK pathway","volume":"70","author":"Bi","year":"2018","journal-title":"Cytotechnology"},{"issue":"6B","key":"10.1016\/j.critrevonc.2026.105152_bib6","first-page":"5203","article-title":"Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells","volume":"19","author":"Boudny","year":"1999","journal-title":"Anticancer Res."},{"issue":"1A","key":"10.1016\/j.critrevonc.2026.105152_bib7","first-page":"7","article-title":"Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells","volume":"23","author":"Boudny","year":"2003","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105152_bib8","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12943-019-1016-0","article-title":"Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy","volume":"18","author":"Cai","year":"2019","journal-title":"Mol. Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105152_bib10","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.3390\/cancers13225671","article-title":"Molecular targets and emerging therapies for advanced gallbladder cancer","volume":"13","author":"Canale","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib11","first-page":"119","article-title":"[Expression of P-glycoprotein in benign and malignant gallbladder neoplasms]","volume":"21","author":"Cao","year":"1999","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105152_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103895","article-title":"Bortezomib-encapsulated dual responsive copolymeric nanoparticles for gallbladder cancer targeted therapy","volume":"9","author":"Chen","year":"2022","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41435-024-00280-9","article-title":"PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer","volume":"25","author":"Chen","year":"2024","journal-title":"Genes Immun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105152_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105152_bib16","series-title":"Molecular Genetics of Drug Resistance","first-page":"247","article-title":"Multidrug resistance in mammalian cells mediated by members of the ATP-binding cassette superfamily: The P-glycoproteins and MRP","author":"Deeley","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105152_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104388","article-title":"Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers","volume":"199","author":"Demir","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105152_bib18","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1007\/s00210-024-03279-1","article-title":"Natural products and long noncoding RNA signatures in gallbladder cancer: a review focuses on pathogenesis, diagnosis, and drug resistance","volume":"397","author":"Elimam","year":"2024","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105152_bib19","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3390\/ijms26062716","article-title":"The role of the tumor microenvironment (TME) in advancing cancer therapies: immune system interactions, tumor-infiltrating lymphocytes (TILs), and the role of exosomes and inflammasomes","volume":"26","author":"Erasha","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib20","first-page":"1869","article-title":"DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage\/repair system","volume":"16","author":"Fang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.yexcr.2014.11.021","article-title":"Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1\u03b1","volume":"332","author":"Gao","year":"2015","journal-title":"Exp. Cell Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105152_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bbrc.2019.06.121","article-title":"PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma","volume":"516","author":"Gong","year":"2019","journal-title":"Biochem Biophys. Res Commun."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105152_bib23","first-page":"12116","article-title":"MiR-1231 enhances docetaxel sensitivity to gallbladder carcinoma cells by downregulating FOXC2","volume":"24","author":"Gong","year":"2020","journal-title":"Eur. Rev. Med Pharm. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105152_bib26","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105152_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206643","article-title":"Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer","volume":"13","author":"Hirosawa","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105152_bib28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41416-025-03011-7","article-title":"Alterations in genomic features and the tumour immune microenvironment predict immunotherapy outcomes in advanced biliary tract cancer patients","volume":"132","author":"Huang","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/jcmm.14851","article-title":"Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer","volume":"24","author":"Huang","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105152_bib30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3892\/or.2021.7947","article-title":"GLI2 but not GLI1\/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer","volume":"45","author":"Ichimiya","year":"2021","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jss.2013.06.003","article-title":"Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-\u03baB activation","volume":"184","author":"Iwase","year":"2013","journal-title":"J. Surg. Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107171","article-title":"Deciphering the role of Enterococcus faecium cytidine deaminase in gemcitabine resistance of gallbladder cancer","volume":"300","author":"Jiang","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"704","key":"10.1016\/j.critrevonc.2026.105152_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add7464","article-title":"PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK","volume":"15","author":"Jiang","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105152_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1169","article-title":"Enhancing the efficacy of immunotherapy using radiotherapy","volume":"9","author":"Keam","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"10391","key":"10.1016\/j.critrevonc.2026.105152_bib35","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105152_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/527534","article-title":"Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma","volume":"2013","author":"Kim","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.critrevonc.2026.105152_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1472-6882-14-254","article-title":"Differentiation therapy: sesamin as an effective agent in targeting cancer stem-like side population cells of human gallbladder carcinoma","volume":"14","author":"Kong","year":"2014","journal-title":"BMC Complement Alter. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/COC.0000000000000989","article-title":"Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies","volume":"46","author":"Lai","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105152_bib39","doi-asserted-by":"crossref","first-page":"9289","DOI":"10.1038\/srep09289","article-title":"The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer","volume":"5","author":"Lee","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105152_bib40","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41418-020-00628-4","article-title":"Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation","volume":"28","author":"Lee","year":"2021","journal-title":"Cell Death Differ."},{"issue":"50","key":"10.1016\/j.critrevonc.2026.105152_bib41","doi-asserted-by":"crossref","first-page":"83060","DOI":"10.18632\/oncotarget.13067","article-title":"MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105152_bib42","first-page":"1699","article-title":"Inhibition of mTOR suppresses human gallbladder carcinoma cell proliferation and enhances the cytotoxicity of 5-fluorouracil by downregulating MDR1 expression","volume":"20","author":"Li","year":"2016","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105152_bib43","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.scib.2024.02.039","article-title":"Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality","volume":"69","author":"Li","year":"2024","journal-title":"Sci. Bull."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105152_bib44","article-title":"3D biomimetic models to reconstitute tumor microenvironment in vitro: spheroids, organoids, and tumor-on-a-chip","volume":"12","author":"Li","year":"2023","journal-title":"Adv. Health Mater."},{"key":"10.1016\/j.critrevonc.2026.105152_bib45","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.2147\/CMAR.S323759","article-title":"Long non-coding RNA myosin light chain Kinase Antisense 1 Plays an oncogenic role in gallbladder carcinoma by promoting chemoresistance and proliferation","volume":"13","author":"Li","year":"2021","journal-title":"Cancer Manag Res."},{"key":"10.1016\/j.critrevonc.2026.105152_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101331","article-title":"OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1\/caspase-3 axis","volume":"16","author":"Lin","year":"2022","journal-title":"Transl. Oncol."},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105152_bib47","doi-asserted-by":"crossref","first-page":"62364","DOI":"10.18632\/oncotarget.11634","article-title":"miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1","volume":"7","author":"Lu","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib48","first-page":"1822","article-title":"Targeting gallbladder cancer: hyaluronan sensitizes cancer cells to chemo-therapeutics","volume":"8","author":"Ma","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105152_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<731::AID-IJC17>3.0.CO;2-H","article-title":"v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells","volume":"80","author":"Masumoto","year":"1999","journal-title":"Int J. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105152_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162854","article-title":"Resistance to Anti-HER2 therapies in gastrointestinal malignancies","volume":"16","author":"Mo","year":"2024","journal-title":"Cancers"},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105152_bib51","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib52","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bbrc.2015.07.080","article-title":"Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK","volume":"464","author":"Nakano","year":"2015","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.critrevonc.2026.105152_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.787897","article-title":"ARID1A Downregulation Predicts High PD-L1 Expression and Worse Clinical Outcome in Patients With Gallbladder Cancer","volume":"12","author":"Nan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105152_bib54","unstructured":"NCCN, 2025. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): Biliary tract cancers (Version 2.2025). \u3008https:\/\/www.nccn.org\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105152_bib55","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jhep.2020.11.033","article-title":"Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes","volume":"74","author":"Nepal","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105152_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.879317","article-title":"Ferroptosis and tumor drug resistance: current status and major challenges","volume":"13","author":"Nie","year":"2022","journal-title":"Front. Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105152_bib57","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105152_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126740","article-title":"LINC00662 Promotes Aggressive Traits by Modulating OCT4 Expression through miR-335-5p in Gallbladder Cancer Cells","volume":"25","author":"P\u00e9rez-Moreno","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105152_bib59","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.7150\/jca.38393","article-title":"Anti-tumor Activity of Bufalin by Inhibiting c-MET Mediated MEK\/ERK and PI3K\/AKT Signaling Pathways in Gallbladder Cancer","volume":"11","author":"Qian","year":"2020","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105152_bib60","first-page":"381","article-title":"[Mechanism research in somatostatin reverting the chemosensitivity of GBC-SD cell line]","volume":"46","author":"Qin","year":"2008","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105152_bib61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/dna.2024.0107","article-title":"SNORA71A Downregulation Enhances Gemcitabine Sensitivity in Gallbladder Cancer Cells by Inducing Ferroptosis Through Inhibiting the AKT\/NRF2\/GPX4 Pathway","volume":"43","author":"Qin","year":"2024","journal-title":"DNA Cell Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib62","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-022-32436-4","article-title":"Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors","volume":"13","author":"Reinbold","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105152_bib63","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1309\/AJCPQT3ELN2BBCKA","article-title":"Gallbladder cancer in Chile: Pathologic characteristics of survival and prognostic factors: analysis of 1,366 cases","volume":"141","author":"Roa","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.critrevonc.2026.105152_bib65","unstructured":"SEER, 2024. SEER Incidence Data, November 2024 Submission (1975-2022). \u3008https:\/\/seer.cancer.gov\/statistics-network\/explorer\/\u3009."},{"key":"10.1016\/j.critrevonc.2026.105152_bib66","article-title":"miRNAs orchestration of gallbladder cancer - Particular emphasis on diagnosis, progression and drug resistance","volume":"248","author":"Shahin","year":"2023","journal-title":"Pathol. Res Pr."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib68","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/j.gastro.2008.06.082","article-title":"Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer","volume":"135","author":"Shibata","year":"2008","journal-title":"Gastroenterology"},{"issue":"13_ement","key":"10.1016\/j.critrevonc.2026.105152_bib69","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1538-7445.AM2021-1010","article-title":"A study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell lines","volume":"81","author":"Stewart","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105152_bib70","article-title":"Global, regional, and national burden and trends analysis of gallbladder and biliary tract cancer from 1990 to 2019 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2019","volume":"11","author":"Su","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105152_bib71","article-title":"A Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab","volume":"7","author":"Sugimori","year":"2024","journal-title":"Cancer Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5582\/ddt.2023.01013","article-title":"Drug resistance and new therapies in gallbladder cancer","volume":"17","author":"Sun","year":"2023","journal-title":"Drug Discov. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105152_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109659","article-title":"Fasting-induced RNF152 resensitizes gallbladder cancer cells to gemcitabine by inhibiting mTORC1-mediated glycolysis","volume":"27","author":"Tao","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105152_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113564","article-title":"Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives","volume":"199","author":"Ten Haaft","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105152_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101149","article-title":"aPKC\u03b9 promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1","volume":"22","author":"Tian","year":"2019","journal-title":"Redox Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105152_bib76","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.3748\/wjg.v9.i12.2817","article-title":"Correlation of P-glycoprotein expression with poor vascularization in human gallbladder carcinomas","volume":"9","author":"Tian","year":"2003","journal-title":"World J. Gastroenterol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105152_bib77","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105152_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087238","article-title":"A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance","volume":"24","author":"Vergara-G\u00f3mez","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib79","first-page":"296","article-title":"Clinical relationship between MDR1 gene and gallbladder cancer","volume":"3","author":"Wang","year":"2004","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00280-020-04100-5","article-title":"Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer","volume":"86","author":"Wang","year":"2020","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105152_bib81","article-title":"Small nucleolar RNA host gene 1 (SNHG1) facilitates gemcitabine chemosensitivity in gallbladder cancer by regulating the miR-23b-3p\/phosphatase and tensin homolog (PTEN) pathway","author":"Wang","year":"2025","journal-title":"Chin. Med. J."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib82","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3892\/or.2012.2156","article-title":"Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation","volume":"29","author":"Wang","year":"2013","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105152_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.178","article-title":"miR-218-5p restores sensitivity to gemcitabine through PRKCE\/MDR1 axis in gallbladder cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105152_bib84","article-title":"Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105152_bib85","article-title":"MCL1 participates in leptin-promoted mitochondrial fusion and contributes to drug resistance in gallbladder cancer","volume":"6","author":"Wang","year":"2021","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105152_bib86","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.bcp.2009.12.006","article-title":"Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation","volume":"79","author":"Wang","year":"2010","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41392-025-02150-w","article-title":"Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2026.105152_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216184","article-title":"YKL-40 derived from infiltrating macrophages cooperates with GDF15 to establish an immune suppressive microenvironment in gallbladder cancer","volume":"563","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105152_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202005064","article-title":"Versatile nanoscale metal\u2013organic frameworks (nMOFs): An emerging 3D nanoplatform for drug delivery and therapeutic applications","volume":"17","author":"Wen","year":"2021","journal-title":"Small"},{"key":"10.1016\/j.critrevonc.2026.105152_bib90","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12935-019-0948-1","article-title":"MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine","volume":"19","author":"Wensheng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.critrevonc.2026.105152_bib91","unstructured":"WHO, 2024. Age-Standardized Rate (World) per 100 000, Incidence, Both sexes, in 2022, Gallbladder (version 1.1). \u3008https:\/\/gco.iarc.who.int\/today\u3009."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105152_bib92","first-page":"5776","article-title":"MicroRNA-181b blocks gensenoside Rg3-mediated tumor suppression of gallbladder carcinoma by promoting autophagy flux via CREBRF\/CREB3 pathway","volume":"11","author":"Wu","year":"2019","journal-title":"Am. J. Transl. Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105152_bib93","doi-asserted-by":"crossref","first-page":"12778","DOI":"10.3390\/ijms150712778","article-title":"Cordycepin down-regulates multiple drug resistant (MDR)\/HIF-1\u03b1 through regulating AMPK\/mTORC1 signaling in GBC-SD gallbladder cancer cells","volume":"15","author":"Wu","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105152_bib94","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fmolb.2020.00070","article-title":"XRCC1 Is a Promising Predictive Biomarker and Facilitates Chemo-Resistance in Gallbladder Cancer","volume":"7","author":"Wu","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105152_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv6723","article-title":"HLF transactivates TFEB to promote gallbladder cancer stem cells' self-renewal and determines tumor response to distinct therapies","volume":"11","author":"Xiang","year":"2025","journal-title":"Sci. Adv."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105152_bib96","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.3748\/wjg.v11.i24.3719","article-title":"Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma","volume":"11","author":"Xu","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105152_bib97","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/MS9.0000000000001665","article-title":"Establishment and characterization of the gemcitabine-resistant human gallbladder cancer cell line NOZ GemR","volume":"86","author":"Xu","year":"2024","journal-title":"Ann. Med Surg. (Lond. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib98","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-019-13420-x","article-title":"Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer","volume":"10","author":"Xu","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib99","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbrc.2019.10.104","article-title":"Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma","volume":"522","author":"Xue","year":"2020","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.critrevonc.2026.105152_bib100","first-page":"1","article-title":"Advances in delivery of chemotherapeutic agents for cancer treatment","volume":"23","author":"Yadav","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.critrevonc.2026.105152_bib101","article-title":"miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105152_bib102","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.7150\/jca.50292","article-title":"Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT","volume":"12","author":"Ye","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105152_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113745","article-title":"UCP2 promotes proliferation and chemoresistance through regulating the NF-\u03baB\/\u03b2-catenin axis and mitochondrial ROS in gallbladder cancer","volume":"172","author":"Yu","year":"2020","journal-title":"Biochem Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105152_bib104","first-page":"3305","article-title":"miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M","volume":"15","author":"Yu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105152_bib105","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3892\/or.2015.3755","article-title":"Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-\u03baB-mediated survival signaling pathways in human gallbladder cancer cells","volume":"33","author":"Yu","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105152_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1452345","article-title":"Aspartate beta-hydroxylase is a prognostic factor in gallbladder cancer with the function of promoting tumorigenesis and chemoresistance","volume":"16","author":"Yuan","year":"2025","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2026.105152_bib107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2015.10.161","article-title":"NOX1 mediates chemoresistance via HIF1\u03b1\/MDR1 pathway in gallbladder cancer","volume":"468","author":"Zhan","year":"2015","journal-title":"Biochem Biophys. Res Commun."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105152_bib108","doi-asserted-by":"crossref","first-page":"10553","DOI":"10.1007\/s13277-016-4957-6","article-title":"miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1","volume":"37","author":"Zhan","year":"2016","journal-title":"Tumour Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib109","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/aps.2012.162","article-title":"Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-\u03baB","volume":"34","author":"Zhang","year":"2013","journal-title":"Acta Pharm. Sin."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105152_bib110","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20194509","article-title":"Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib111","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21739","article-title":"Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp)","volume":"41","author":"Zhang","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105152_bib112","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1080\/15384101.2019.1676581","article-title":"Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response","volume":"18","author":"Zhang","year":"2019","journal-title":"Cell Cycle"},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105152_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202406633","article-title":"PTBP3 Mediates IL-18 Exon Skipping to Promote Immune Escape in Gallbladder Cancer","volume":"11","author":"Zhao","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.critrevonc.2026.105152_bib114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.omto.2021.08.016","article-title":"lncRNA RP11-147L13.8 suppresses metastasis and chemo-resistance by modulating the phosphorylation of c-Jun protein in GBC","volume":"23","author":"Zheng","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105152_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s42114-025-01292-3","article-title":"Therapeutic applications and potential biological barriers of nano-delivery systems in common gastrointestinal disorders: a comprehensive review","volume":"8","author":"Zheng","year":"2025","journal-title":"Adv. Compos Hybrid. Mater."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.surg.2010.12.010","article-title":"Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells","volume":"150","author":"Zhou","year":"2011","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105152_bib117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41698-023-00409-5","article-title":"PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system","volume":"7","author":"Zimmer","year":"2023","journal-title":"NPJ Precis Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:21:17Z","timestamp":1774005677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":117,"alternative-id":["S1040842826000399"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105152","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifaceted mechanisms and precision strategies to overcome therapeutic resistance in gallbladder cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105152"}}